Compare PRAX & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CHE |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | 2020 | 1994 |
| Metric | PRAX | CHE |
|---|---|---|
| Price | $322.54 | $487.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $572.13 | $501.50 |
| AVG Volume (30 Days) | ★ 548.0K | 191.7K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 4.84 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | N/A | $6.56 |
| Revenue Next Year | $7,758.26 | $6.23 |
| P/E Ratio | ★ N/A | $101.37 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $37.25 | $365.21 |
| 52 Week High | $366.52 | $492.30 |
| Indicator | PRAX | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 67.71 |
| Support Level | $282.49 | $418.47 |
| Resistance Level | $344.07 | N/A |
| Average True Range (ATR) | 21.29 | 11.23 |
| MACD | 2.92 | 2.76 |
| Stochastic Oscillator | 54.65 | 89.63 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.